ArticleACS medicinal chemistry letters2018
Meridianin D Analogues Display Antibiofilm Activity against MRSA and Increase Colistin Efficacy in Gram-Negative Bacteria.
Article in ACS medicinal chemistry letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 54 citations in OpenAlex.
- Synthesis and antibacterial evaluation of trisindolines against methicillin-resistant Staphylococcus aureus targeting cell membrane.NPJ biofilms and microbiomes · 2025Article
- Catechol-substituted siderophore colistin exhibits superior antimicrobial activity than its unmodified polypeptide counterpart.BMC chemistry · 2025Article
- Synthesis, pharmacokinetic studies, and metabolite analysis of meridianin C in rats using a validated ultra high performance liquid chromatography-tandem mass spectrometry method.Frontiers in pharmacology · 2025Article
- Anti-Biofilm Extracts and Molecules from the Marine Environment.Marine drugs · 2024Review
- Assessing the synergistic potential of bacteriophage endolysins and antimicrobial peptides for eradicating bacterial biofilms.Archives of microbiology · 2024Article
- War and peace: exploring microbial defence systems as a source of new antimicrobial therapies.Frontiers in pharmacology · 2024Review
- PYED-1 Overcomes Colistin Resistance inPathogens (Basel, Switzerland) · 2023Article
- The Synthesis and Biological Evaluation of 2-(1Molecules (Basel, Switzerland) · 2023Article
- 6-Bromoindirubin-3'-oxime derivatives are highly active colistin adjuvants againstRSC medicinal chemistry · 2023Article
- Antibacterial and Antibiofilm Activities of Sertindole and Its Antibacterial Mechanism againstACS omega · 2023Article
- A Review: Meridianins and Meridianins Derivatives.Molecules (Basel, Switzerland) · 2022Review
- Discovery and Preliminary Structure-Activity Investigation of 3-Substituted-1Antibiotics (Basel, Switzerland) · 2022Article
- Meridianins Inhibit GSK3β In Vivo and Improve Behavioral Alterations Induced by Chronic Stress.Marine drugs · 2022Article
- Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA.ACS medicinal chemistry letters · 2022Article
- Benzimidazole Isosteres of Salicylanilides Are Highly Active Colistin Adjuvants.ACS infectious diseases · 2021Article
- Evaluation of small molecule kinase inhibitors as novel antimicrobial and antibiofilm agents.Chemical biology & drug design · 2021Review
- Strategies and Approaches for Discovery of Small Molecule Disruptors of Biofilm Physiology.Molecules (Basel, Switzerland) · 2021Review
- A scaffold hopping strategy to generate new aryl-2-amino pyrimidine MRSA biofilm inhibitors.RSC medicinal chemistry · 2021Article
- Current Update on Intrinsic and Acquired Colistin Resistance Mechanisms in Bacteria.Frontiers in medicine · 2021Review
- Synthesis and biofilm inhibition studies of 2-(2-amino-6-arylpyrimidin-4-yl)quinazolin-4(3H)-ones.Bioorganic & medicinal chemistry letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last 30 years, development of new classes of antibiotics has slowed, increasing the necessity for new options to treat multidrug resistant bacterial infections. Development of antibiotic adjuvants that increase the effectiveness of currently available antibiotics is a promising alternative approach to classical antibiotic development. Reports of the ability of the natural product meridianin D to modulate bacterial behavior have been rare. Herein, we describe the ability of meridianin D to inhibit biofilm formation of methicillin-resistant
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.